Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

MAP Verified Summary — reported by NPR Politics

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.

This story’s context record documents 7 observable dimensions — Origin, Attribution, Specificity, Timing, Framing, Context Change, and Information Relationships — as part of Media Alert Press’s context-documentation ledger. MAP does not score or rate this content. Read the full original story at NPR Politics →

View MAP Context →